485 related articles for article (PubMed ID: 11965534)
21. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
22. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
23. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Mitani Y; Oue N; Hamai Y; Aung PP; Matsumura S; Nakayama H; Kamata N; Yasui W
J Pathol; 2005 Jan; 205(1):65-73. PubMed ID: 15586362
[TBL] [Abstract][Full Text] [Related]
24. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
25. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy.
Zhu N; Gu L; Findley HW; Li F; Zhou M
Oncogene; 2004 Sep; 23(45):7545-51. PubMed ID: 15334064
[TBL] [Abstract][Full Text] [Related]
26. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
27. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
28. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
29. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
Bergamaschi D; Samuels Y; O'Neil NJ; Trigiante G; Crook T; Hsieh JK; O'Connor DJ; Zhong S; Campargue I; Tomlinson ML; Kuwabara PE; Lu X
Nat Genet; 2003 Feb; 33(2):162-7. PubMed ID: 12524540
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
[TBL] [Abstract][Full Text] [Related]
31. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis.
Wall NR; O'Connor DS; Plescia J; Pommier Y; Altieri DC
Cancer Res; 2003 Jan; 63(1):230-5. PubMed ID: 12517802
[TBL] [Abstract][Full Text] [Related]
32. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
33. Growth factor-dependent regulation of survivin by c-myc in human breast cancer.
Cosgrave N; Hill AD; Young LS
J Mol Endocrinol; 2006 Dec; 37(3):377-90. PubMed ID: 17170079
[TBL] [Abstract][Full Text] [Related]
34. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
[TBL] [Abstract][Full Text] [Related]
35. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein.
Cajot JF; Anderson MJ; Lehman TA; Shapiro H; Briggs AA; Stanbridge EJ
Cancer Res; 1992 Dec; 52(24):6956-60. PubMed ID: 1458487
[TBL] [Abstract][Full Text] [Related]
36. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
[TBL] [Abstract][Full Text] [Related]
37. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
[TBL] [Abstract][Full Text] [Related]
38. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.
Strauss BE; Shivakumar C; Deb SP; Deb S; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(3):825-31. PubMed ID: 8554604
[TBL] [Abstract][Full Text] [Related]
39. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
40. Compromised HOXA5 function can limit p53 expression in human breast tumours.
Raman V; Martensen SA; Reisman D; Evron E; Odenwald WF; Jaffee E; Marks J; Sukumar S
Nature; 2000 Jun; 405(6789):974-8. PubMed ID: 10879542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
